Table 5.
Baseline characteristics of participants with coronary heart disease (CHD) by treatment group (n=506).
|
|
Control (n=250) | Intervention (n=256) | Total | ||||
| Age (years), mean (SD) | 64.8 (11.1) | 63.2 (10.4) | 64.0 (10.8) | ||||
| Sex, n (%) | |||||||
|
|
Female | 47 (18.8) | 38 (14.8) | 85 (16.8) | |||
|
|
Male | 203 (81.2) | 218 (85.2) | 421 (83.2) | |||
| Ethnicity, n (%) | |||||||
|
|
Australian or New Zealander | 132 (52.8) | 135 (52.7) | 267 (52.8) | |||
|
|
Asian | 51 (20.4) | 42 (16.4) | 93 (18.4) | |||
|
|
Other | 67 (26.8) | 79 (30.9) | 146 (28.9) | |||
| Marital status, n (%) | |||||||
|
|
Married or de facto partnership | 185 (74) | 183 (71.5) | 368 (72.7) | |||
|
|
Single, separated, or widowed | 65 (26) | 73 (28.5) | 138 (27.3) | |||
| Years of formal education, mean (SD) | 13.4 (4.1) | 13.8 (4.4) | 13.6 (4.2) | ||||
| Employment status, n (%) | |||||||
|
|
Working full time | 84 (33.6) | 88 (34.4) | 172 (34) | |||
|
|
Working part-time | 18 (7.2) | 19 (7.4) | 37 (7.3) | |||
|
|
Not working | 148 (59.2) | 149 (58.2) | 297 (58.7) | |||
| History of CHD, n (%) | |||||||
|
|
All CHD | 250 (100) | 256 (100) | 506 (100) | |||
|
|
Myocardial infarction | 149 (59.6) | 160 (62.5) | 309 (61.1) | |||
|
|
CABGsa | 74 (29.6) | 68 (26.6) | 142 (28.1) | |||
|
|
PCIb | 154 (61.6) | 163 (63.7) | 317 (62.6) | |||
| History of type 1 diabetes, n (%) | 3 (1.2) | 1 (0.4) | 4 (0.8) | ||||
| History of type 2 diabetes, n (%) | 125 (50) | 121 (47.3) | 246 (48.6) | ||||
| Family history of CHD, n (%) | 151 (60.6)c | 172 (67.7)d | 323 (64.2)e | ||||
| Family history of diabetes, n (%) | 112 (44.8) | 124 (49.2)f | 236 (47)g | ||||
| Referral source, n (%) | |||||||
|
|
Specialist or hospital | 191 (76.7)c | 201 (78.5) | 392 (77.5) | |||
|
|
GPh or community | 58 (23.3)c | 55 (21.5) | 113 (22.3) | |||
| Current smoker, n (%) | 26 (10.5)i | 24 (9.5)f | 50 (10)j | ||||
| Current drinker, n (%) | 134 (54.3)i | 158 (62.7)f | 292 (58.5)j | ||||
| Exercises regularly, n (%) | 103 (41.7)i | 113 (44.8)f | 216 (43.3)j | ||||
| Total physical activity (METk minutes per week), mean (SD) | 1834 (2748) | 2185 (3874) | 2010 (3361) | ||||
| SBPl (mm Hg), mean (SD) | 128.8 (17.5) | 126.6 (17.6) | 127.7 (17.5) | ||||
| DBPm (mm Hg), mean (SD) | 77.0 (11.4) | 76.0 (10.3) | 76.5 (10.9) | ||||
| BMI (kg/m2), mean (SD) | 30.0 (6.2) | 31.2 (6.3) | 30.6 (6.3) | ||||
| Waist circumference (cm), mean (SD) | 106.0 (14.8) | 109.1 (16.2) | 107.5 (15.6) | ||||
| Heart rate, mean (SD) | 71.0 (12.2) | 69.9 (11.6) | 70.4 (11.9) | ||||
| LDLn cholesterol (mmol/L), mean (SD) | 1.9 (0.8) | 1.9 (0.9) | 1.9 (0.9) | ||||
| HDLo cholesterol (mmol/L), mean (SD) | 1.1 (0.3) | 1.1 (0.3) | 1.1 (0.3) | ||||
| Total cholesterol (mmol/L), mean (SD) | 3.9 (1.1) | 3.9 (1.1) | 3.9 (1.1) | ||||
| Triglycerides (mmol/L), mean (SD) | 2.0 (2.3) | 1.8 (1.2) | 1.9 (1.8) | ||||
| Fasting glucose (mmol/L), mean (SD) | 7.6 (3.2) | 7.1 (2.7) | 7.3 (3.0) | ||||
| Antihypertensive medication, n (%) | |||||||
|
|
ACEp inhibitors | 92 (36.8) | 98 (38.3) | 190 (37.5) | |||
|
|
Angiotensin 2 receptor blockers | 66 (26.4) | 74 (28.9) | 140 (27.7) | |||
|
|
Thiazide diuretics | 20 (8) | 23 (9) | 43 (8.5) | |||
|
|
β-blockers | 137 (54.8) | 149 (58.2) | 286 (56.5) | |||
|
|
Calcium channel blockers | 52 (20.8) | 65 (25.4) | 117 (23.1) | |||
|
|
Other antihypertensives | 36 (14.4) | 44 (17.2) | 80 (15.8) | |||
aCABG: coronary artery bypass graft.
bPCI: percutaneous coronary intervention.
cn=249.
dn=254.
en=503.
fn=252.
gn=502.
hGP: general practice.
in=247.
jn=499.
kMET: metabolic equivalent of task.
lSBP: systolic blood pressure.
mDBP: diastolic blood pressure.
nLDL: low-density lipoprotein.
oHDL: high-density lipoprotein.
pACE: angiotensin-converting enzyme.